Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nucleotide depletion reveals the impaired ribosome biogenesis checkpoint as a barrier against damage

  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Riaño-Canalias, Ferran
  • Almacellas, Eugènia|||0000-0002-7726-8430
  • Mauvezin, Caroline|||0000-0003-4220-7272
  • Samino, Sara
  • Feu, Sonia
  • Menoyo, Sandra
  • Domostegui, Ana
  • Garcia-Cajide, Marta
  • Salazar, Ramón
  • Cortes Crignola, Constanza|||0000-0001-7254-9607
  • Marcos, Ricard|||0000-0001-7891-357X
  • Tauler, Albert
  • Yanes, Oscar|||0000-0003-3695-7157
  • Agell, Neus|||0000-0002-1205-6074
  • Kozma, Sara C.
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
Many oncogenes enhance nucleotide usage to increase ribosome content, replication, and cell proliferation, but in parallel trigger p53 activation. Both the impaired ribosome biogenesis checkpoint () and the damage response () have been implicated in p53 activation following nucleotide depletion. However, it is difficult to reconcile the two checkpoints operating together, as the induces p21-mediated G1 arrest, whereas the requires that cells enter S phase. Gradual inhibition of inosine monophosphate dehydrogenase (), an enzyme required for de novo synthesis, reveals a hierarchical organization of these two checkpoints. We find that the is the primary nucleotide sensor, but increased inhibition leads to p21 degradation, compromising -mediated G1 arrest and allowing S phase entry and activation. Disruption of the alone is sufficient to elicit the , which is strongly enhanced by inhibition, suggesting that the acts as a barrier against genomic instability. Hierarchical organization of p21-mediated G1 arrest and S-phase damage response signaling ensures genomic stability upon increasing inhibition of nucleotide synthesis enzyme.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis

  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Winkler, René|||0000-0002-7570-0242
  • Casquero, Raquel
  • Muhar, Matthias|||0000-0002-3018-9698
  • van der Garde, Mark
  • Maher, Michael|||0000-0002-4956-7185
  • Martínez Herráez, Carolina|||0000-0003-4711-7225
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Fellner, Michaela
  • Rathert, Philipp|||0000-0003-1477-136X
  • Brooks, Nigel
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Gentilella, Antonio|||0000-0002-6830-2086
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Zuber, Johannes|||0000-0001-8810-6835
  • Götze, Katharina S.|||0000-0002-6276-8002
  • Buschbeck, Marcus|||0000-0002-3218-4567
The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. New treatment options are urgently needed to improve the clinical management of these patients. Here, we perform a loss-of-function shRNA screen and identify the histone acetyl transferase and transcriptional co-activator, CREB binding protein (CBP), as a major regulator of AZA sensitivity. Compounds inhibiting the activity of CBP and the closely related p300 synergistically reduce viability of MDS-derived AML cell lines when combined with AZA. Importantly, this effect is specific for the RNA-dependent functions of AZA and not observed with the related compound decitabine that is only incorporated into DNA. The identification of immediate target genes leads us to the unexpected finding that the effect of CBP/p300 inhibition is mediated by globally down regulating protein synthesis.